| Similar Articles |
|---|
 |
The Motley Fool
September 18, 2007
Brian Lawler |
Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year.   |
The Motley Fool
November 30, 2006
Brian Lawler |
Durect's Pain-Free Deal A partnership deal has investors in the small specialty pharma excited. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
January 6, 2012
David Williamson |
Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares. |
The Motley Fool
May 2, 2007
Brian Lawler |
Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about. |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
June 27, 2011
Brian Orelli |
Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections. |
The Motley Fool
March 1, 2007
Brian Lawler |
Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works. |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
December 11, 2008
Brian Orelli |
A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
June 24, 2011
Brian Orelli |
Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why? |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
The Motley Fool
November 2, 2007
Brian Lawler |
A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note. |
The Motley Fool
August 29, 2011
Brian Orelli |
A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Nursing
October 2009
Yvonne D'Arcy |
Overturning barriers to pain relief in older adults This article will describe how to lower the barriers to effective pain control in older patients and provide practical tips for helping them receive the full benefit from pharmacologic and nonpharmacologic therapies. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
American Journal of Nursing
April 2010
Mary Curry Narayan |
Culture's Effects on Pain Assessment and Management When patients belong to a culture or speak a language that's different from that of their health care provider, the provider faces additional challenges in successfully assessing and managing the patients' pain. |
The Motley Fool
June 20, 2011
Brian Orelli |
Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next. |
